News Releases

Date Title and Summary View
December 3, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Dec. 3, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 18,000 shares of...
Additional Formats
November 10, 2021
– Positive End-of-Phase 2 Meeting Completed – – Phase 3 Trial Dosing Expected Q1 2022 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 10, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and...
Additional Formats
November 9, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 9, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a...
Additional Formats
November 8, 2021
– KVD900 Phase 2 data presented at American College of Allergy , Asthma & Immunology Annual Scientific Meeting – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 8, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...
Additional Formats
November 4, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 4, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 23,000 shares of...
Additional Formats
October 4, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 4, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 40,000 shares of...
Additional Formats
September 21, 2021
CAMBRIDGE, Mass. & SALISBURY, United Kingdom --(BUSINESS WIRE)--Sep. 21, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will...
Additional Formats
September 14, 2021
– US Site Initiations Ongoing – – Regulatory Submissions Complete for All Countries Participating in Trial – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 14, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...
Additional Formats
September 9, 2021
– FDA End-of-Phase 2 Meeting for KVD900 Oral HAE Phase 3 Program Scheduled for This Month – – KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 9, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...
Additional Formats
September 2, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 2, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 43,000 shares of...
Additional Formats
Displaying 1 - 10 of 27